MELLARIL Drug Patent Profile

« Back to Dashboard

Which patents cover Mellaril, and when can generic versions of Mellaril launch?

Mellaril is a drug marketed by Novartis and is included in two NDAs.

The generic ingredient in MELLARIL is thioridazine. There are two drug master file entries for this compound. Additional details are available on the thioridazine profile page.

Summary for MELLARIL

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	1
Patent Applications:	5,081
DailyMed Link:	MELLARIL at DailyMed

Recent Clinical Trials for MELLARIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
New Mexico Cancer Care Alliance	Early Phase 1
Oxnard Foundation	Early Phase 1

See all MELLARIL clinical trials

US Patents and Regulatory Information for MELLARIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	MELLARIL	thioridazine hydrochloride	CONCENTRATE;ORAL	011808-012	Approved Prior to Jan 1, 1982		DISCN	No	No
Novartis	MELLARIL	thioridazine hydrochloride	TABLET;ORAL	011808-009	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Novartis	MELLARIL	thioridazine hydrochloride	TABLET;ORAL	011808-016	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Novartis	MELLARIL	thioridazine hydrochloride	TABLET;ORAL	011808-017	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Mellaril (Thioridazine) Market Dynamics, Financial Trajectory, Patent Status, and Generic Risk

Last updated: October 20, 2026

Mellaril, the brand name for thioridazine hydrochloride, is a legacy first-generation antipsychotic with no meaningful current branded market. Its commercial decline resulted from clinical substitution by newer antipsychotics and safety restrictions involving QT-interval prolongation and torsades de pointes risk. Novartis discontinued Mellaril in the United States, and the product no longer has a viable branded revenue base. Any residual demand is limited to rare clinical situations involving generic thioridazine, where available.

Public sources do not provide reliable standalone revenue figures for Mellaril. The drug’s financial trajectory is therefore best assessed through regulatory withdrawal, therapeutic substitution, patent expiry, generic availability, and the loss of commercial distribution.

What is Mellaril and what happened to its market?

Mellaril is thioridazine hydrochloride, a piperidine phenothiazine antipsychotic formerly used to treat schizophrenia and other psychotic disorders. It was introduced before the modern atypical antipsychotic class and competed with chlorpromazine, fluphenazine, haloperidol, and later risperidone, olanzapine, quetiapine, and ziprasidone.

Its market position deteriorated for two reasons:

1. Newer antipsychotics offered broader prescribing utility and more favorable commercial positioning.
2. Thioridazine carried material cardiac safety restrictions, particularly QT prolongation and ventricular arrhythmia risk.

The FDA label required thioridazine to be reserved for patients who failed to respond adequately to other antipsychotics or could not tolerate them because of the risk of potentially fatal cardiac arrhythmias.[1] The label also identified dose-related QT prolongation and contraindicated use with drugs that inhibit CYP2D6 or otherwise increase thioridazine exposure.

Novartis discontinued Mellaril in the United States. The brand’s withdrawal removed the principal commercial product from the market, leaving any remaining opportunity to generic manufacturers rather than to the original brand owner.[2]

When did Mellaril lose exclusivity?

Mellaril lost meaningful market exclusivity before its commercial discontinuation. Thioridazine is an old small-molecule active ingredient, and its foundational composition-of-matter protection, if any, expired many years before the product’s withdrawal.

Commercial factor	Mellaril status
Active ingredient	Thioridazine hydrochloride
Drug class	First-generation phenothiazine antipsychotic
Original commercial period	Mid-20th century through early 2000s
Composition-of-matter exclusivity	Expired decades ago
Brand manufacturer	Novartis, following predecessor-company ownership
Generic competition	Historically available or attempted
Brand discontinuation	United States market discontinued by Novartis
Current branded revenue	No material ongoing revenue base
Biosimilar exposure	Not applicable
Main commercial barrier	Weak demand, safety restrictions, limited supply, and clinical substitution

The relevant commercial loss occurred through ordinary patent expiry and therapeutic obsolescence rather than through a recent Paragraph IV dispute or a late-life patent cliff.

What patents protected Mellaril?

No commercially relevant, unexpired U.S. patent estate is associated with Mellaril today. The original thioridazine molecule is an established generic compound. Any historical compound, formulation, process, or use patents would have expired long before the current period.

Formulation patents

Mellaril was marketed primarily as oral tablets. Historical formulation protection may have covered tablet composition, manufacturing processes, or dosage forms, but those rights do not create current market exclusivity. The underlying molecule is sufficiently old that an entrant would generally focus on FDA approval, manufacturing economics, supply continuity, and product liability rather than patent clearance.

Method-of-use patents

No current method-of-use patent is known to provide meaningful exclusivity for thioridazine in schizophrenia or related psychiatric indications. The FDA-approved use is narrow because of safety restrictions, and physicians have largely shifted toward newer antipsychotics.

Manufacturing and process protection

Manufacturing know-how could create practical barriers, especially for a low-volume product with specialized active-pharmaceutical-ingredient supply. Those barriers are commercial rather than patent-based. A manufacturer would need validated production, quality controls, stability data, and a dependable supply chain for an aging product with limited demand.

What is the FDA regulatory status of Mellaril?

Mellaril is not a commercially active branded FDA product. The FDA-approved labeling for thioridazine contains strong cardiac safety warnings and restricts use to patients who do not respond to or cannot tolerate other antipsychotics.[1]

The principal regulatory issues are:

• QTc prolongation.
• Risk of torsades de pointes and sudden death.
• Dose-related cardiac toxicity.
• Interaction risk through CYP2D6 inhibition.
• Contraindicated use with other QT-prolonging or metabolism-inhibiting drugs.
• Need for careful patient selection and monitoring.

The FDA has not granted thioridazine the regulatory profile associated with a modern first-line antipsychotic. Its label positioning is effectively that of a restricted, last-line therapy.

Orange Book status

The Orange Book is relevant to approved thioridazine tablets and any listed generic equivalents, but the practical commercial question is whether an active manufacturer is currently supplying the product. A historical Orange Book listing does not establish current market availability or meaningful revenue opportunity.

Because Mellaril is discontinued as a brand, there is no current branded Orange Book franchise comparable to an active innovator product. Any remaining listings would relate to generic thioridazine products rather than to continuing Mellaril brand sales.[3]

How did safety concerns affect Mellaril sales?

Safety concerns accelerated the product’s decline after the introduction of atypical antipsychotics. Thioridazine’s cardiac warning made it less attractive to prescribers, hospitals, formularies, and managed-care organizations.

The FDA required that thioridazine be used only after inadequate response or intolerance to other antipsychotic treatments. That requirement reduced the eligible patient population and increased the monitoring burden. It also weakened the product’s position in institutional formularies.

The safety profile affected market economics in four ways:

1. It reduced new-patient prescriptions.
2. It increased switching to risperidone, olanzapine, quetiapine, and other alternatives.
3. It raised physician and pharmacy screening costs.
4. It reduced the commercial value of maintaining a branded sales infrastructure.

The decline was therefore structural. A price cut or promotional campaign could not restore the former market because the principal problem was clinical positioning.

How did Mellaril compare with competing antipsychotics?

Product	Active ingredient	Market generation	Commercial position versus Mellaril	Key competitive advantage
Mellaril	Thioridazine	First generation	Legacy, restricted use	Low-cost historical therapy
Thorazine	Chlorpromazine	First generation	Older low-cost alternative	Long clinical history
Haldol	Haloperidol	First generation	Stronger institutional presence	Broad use, injectable formulation
Risperdal	Risperidone	Second generation	Major substitute	Broad adoption and commercial scale
Zyprexa	Olanzapine	Second generation	Major substitute	Strong efficacy and marketing position
Seroquel	Quetiapine	Second generation	Major substitute	Broad psychiatric use and formulation range
Geodon	Ziprasidone	Second generation	Competitive alternative	Different metabolic profile, although QT concerns remained

Mellaril was particularly disadvantaged against atypical antipsychotics because its cardiac risk was visible in labeling while competitors offered broader commercial positioning and greater physician familiarity.

What was Mellaril’s financial trajectory?

Mellaril’s financial trajectory followed five stages.

Early commercial adoption

The drug benefited from limited competition in the treatment of schizophrenia during the era when phenothiazines were central to psychiatric care. Revenue was supported by chronic use and recurring prescriptions.

Generic and therapeutic pressure

As generic versions and competing first-generation antipsychotics became available, price competition reduced brand economics. The arrival of atypical antipsychotics created a more serious threat because the new products competed on clinical positioning, not only price.

Safety-driven contraction

The boxed warning and restricted-use positioning reduced prescription volume. Cardiac monitoring requirements and interaction concerns weakened formulary demand.

Brand discontinuation

Novartis discontinued Mellaril in the United States. The decision reflected the product’s declining commercial value and the cost of maintaining supply, regulatory compliance, pharmacovigilance, and distribution for a low-demand medicine.[2]

Residual generic niche

Any later sales opportunity was limited to generic thioridazine. Such a market would typically have low volume, limited pricing power, intermittent supply, and uncertain manufacturer participation. The product has no credible path to large-scale revenue recovery absent a major change in clinical practice, which is unlikely under the existing safety profile.

Are there Paragraph IV challenges or patent lawsuits involving Mellaril?

No current Paragraph IV campaign or major active patent litigation is associated with Mellaril. The product’s relevant patent estate is too old to support a contemporary branded-exclusivity strategy.

Historical generic entry may have involved ordinary ANDA activity, but that is materially different from a current patent challenge against an active innovator franchise. There is no known settlement structure comparable to those used for high-value branded drugs approaching loss of exclusivity.

Litigation question	Mellaril assessment
Active innovator patent dispute	None of commercial significance identified
Current Paragraph IV risk	Not material
Patent settlement	No commercially relevant current settlement identified
Regulatory exclusivity dispute	Not material
Generic injunction risk	Low
Product liability exposure	More relevant than patent litigation

For a potential entrant, the principal legal risks would be product liability, labeling compliance, manufacturing quality, and supply obligations rather than infringement litigation.

Does Mellaril face biosimilar risk?

No. Mellaril is a synthetic small-molecule drug, not a biologic. Biosimilar regulation does not apply.

The relevant competitive category is generic substitution. Generic manufacturers do not need to demonstrate biosimilarity; they generally rely on an abbreviated pathway demonstrating pharmaceutical equivalence and bioequivalence to the reference product, subject to applicable FDA requirements.[4]

What generic entry risks exist for thioridazine?

Generic entry is technically possible but commercially unattractive. The key risks include:

• Small and declining patient demand.
• Limited prescriber willingness to use the product.
• Cardiac monitoring and contraindication requirements.
• Potential shortages if only one or two suppliers remain.
• Low revenue per prescription.
• Manufacturing costs that may not be covered by market volume.
• Product liability risk associated with arrhythmias.
• Difficulty obtaining consistent active-ingredient supply.
• Reputational risk from marketing a restricted legacy medicine.

The absence of patent barriers does not guarantee a viable generic business. For thioridazine, market size and safety economics are more important than exclusivity.

Which companies are challenging Mellaril’s market?

No current company is pursuing a large-scale branded challenge to Mellaril because the original franchise has already lost commercial relevance. The competitive pressure came from established antipsychotics marketed by companies such as Janssen, Eli Lilly, AstraZeneca, and Pfizer, rather than from a single generic challenger.

The market shifted from thioridazine to newer agents through prescribing substitution, formulary decisions, and safety preferences. Generic manufacturers may supply thioridazine where demand exists, but they do not represent a strategic threat to an active Mellaril brand.

What is the geographic coverage of Mellaril’s remaining market?

The remaining market is highly fragmented by country. Regulatory status, manufacturer participation, hospital procurement, and national reimbursement policies determine whether thioridazine is available.

The United States has no meaningful branded Mellaril market. In other jurisdictions, thioridazine may have historical registrations or limited generic availability, but global sales cannot be inferred from legacy registration records. A company evaluating the product would need to treat each country as a separate low-volume opportunity rather than assume broad international availability.

The most relevant geographic variables are:

• Local approval status.
• Active marketing authorization holder.
• Current product listing.
• National shortage history.
• Hospital versus community prescribing.
• Local pharmacovigilance requirements.
• Import and active-ingredient controls.

How strong is the Mellaril patent estate?

The current patent estate is commercially weak to nonexistent.

Patent-estate dimension	Assessment
Composition-of-matter protection	Expired
Current formulation exclusivity	No meaningful protection identified
Method-of-use exclusivity	No meaningful protection identified
Pediatric exclusivity	Not commercially relevant
Orphan-drug exclusivity	Not identified
Data exclusivity	Expired
Patent litigation leverage	Minimal
Manufacturing know-how	Possible, but not equivalent to exclusivity
Overall strength	Very weak

Mellaril has no credible patent-based defense against generic competition. The product’s commercial barriers arise from low demand and safety concerns.

What is the outlook for Mellaril revenue?

The revenue outlook is effectively flat at a negligible level. There is no evidence of a durable branded revenue stream, and the product lacks the patent, regulatory, or clinical attributes needed for a recovery.

A realistic scenario analysis is:

Scenario	Revenue implication
Continued restricted generic use	Small, unstable niche sales
Additional supplier exit	Lower availability and possible shortages
Renewed branded launch	Economically unattractive without a major clinical change
New formulation development	High regulatory and commercial risk
Large-scale generic expansion	Unlikely because demand is limited
Patent-driven price protection	Not available

Standalone Mellaril revenue cannot be reliably quantified from public company disclosures because the product was not separately reported after becoming immaterial within the manufacturer’s portfolio. The financial conclusion is nevertheless clear: Mellaril moved from a recurring chronic-therapy product to a discontinued legacy medicine with little remaining commercial value.

Key Takeaways

• Mellaril is the former brand name for thioridazine hydrochloride.
• Novartis discontinued the U.S. brand after the product lost clinical and commercial relevance.
• QT prolongation and ventricular arrhythmia risk materially weakened demand.
• The underlying molecule has been off patent for decades.
• No current patent estate provides meaningful exclusivity.
• Paragraph IV litigation and patent settlements are not material to the product’s present outlook.
• Biosimilar risk does not apply because thioridazine is a small molecule.
• Any residual market is limited to low-volume generic use.
• Public companies do not disclose reliable standalone Mellaril revenue.
• The product has no credible path to a substantial branded revenue recovery.

FAQs

Is Mellaril still prescribed for schizophrenia?

It may be used in rare, highly selected cases, but FDA labeling restricts thioridazine to patients who fail to respond adequately to other antipsychotics or cannot tolerate them.[1]

Is thioridazine still available as a generic?

Availability depends on current manufacturer participation and country-specific distribution. Historical approval or listing does not establish continuous commercial supply.

Did Mellaril have a patent that blocked generic competition?

Any relevant original patents expired long ago. Current generic competition is not materially constrained by patent protection.

Why was Mellaril discontinued?

The product lost demand because of competition from newer antipsychotics and serious cardiac safety concerns that limited its use. Novartis discontinued the U.S. brand as the commercial market contracted.[2]

Could a new thioridazine formulation revive the product?

A new formulation would face substantial clinical, regulatory, liability, and market-adoption barriers. It would not restore the old Mellaril franchise without evidence of a meaningful safety or therapeutic advantage.

References

1. U.S. Food and Drug Administration. (2005). Mellaril (thioridazine hydrochloride) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2005). Drug products withdrawn or removed from the market for reasons of safety or effectiveness. Federal Register.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process for generic drugs. FDA.